Relay Therapeutics rises on interim data for cancer drug

Relay Therapeutics

11/12/2024 11:43

** Shares of Relay Therapeutics  RLAY.O  rise 7.5% to $4.76
premarket   
    ** Co says its lead drug candidate to treat a type of
locally advanced breast cancer helped patients live for about
11.4 months on average without the disease getting worse    
    ** The drug, RLY-2608, is being tested in combination with
hormone therapy   
     ** RLAY plans to start a pivotal study testing the
combination next year 
    ** The combination was generally well tolerated in the 118
patients treated -RLAY
    ** Two patients discontinued treatment due to
treatment-related side-effects such as nausea and loss of
appetite 
    ** Up to last close, stock down ~60% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))